Strategy

Our latest review reveals that those companies scoring well on profit management metrics are best positioned to maintain that crucial edge in performance execution.

A review of a recent FSP in which the CRO partner assumed clinical monitoring and site support responsibility for more than 50 ongoing trials.

Following the unveiling of the UK’s post-Brexit life sciences strategy, Neil Grubert looks at the measures related to market access, a particular challenge in the UK market and key to its future success in the sector.

As regulators lower evidentiary requirements for approval to speed development and review of new drugs for unmet medical needs, payers are demanding more data to justify price premiums. Companies need to be strategic in how they navigate these complexities, write Bengt Anell, Sangeeta Budhia and Richard Macaulay.

Experts assess the current pharma dealmaking landscape-one where, despite market headwinds, is still heavily influenced by factors under the buyer and seller’s control.

In the first of three blogs on how digital strategy and a “data culture” can help define and deliver value, David Ormesher focuses on Value Creation.

Big data has proven to be a valuable business asset, but using it to gain competitive advantage requires the right combination of strategy, technology and execution, write Mahmood Majeed, Vickye Jain, and Sandeep Varma.

With the patient voice growing louder in all aspects of the drug development and commercialization journey, Pharm Exec examines some of the current industry thinking on the evolving pharma-patient relationship.

Jackie DeAngelis outlines three common mistakes that hinder access attainment when launching a new drug.

For pharma, diagnosing what ails or strengthens performance in this critical corporate discipline may help reshape business prognosis.

Study examines why a pharma brand’s early sales are not a trusted predictor for total lifetime value-it’s about driving waves of growth.

Pharm Exec's Editorial Advisory Board member, Peter Young, cover a summary of the strategic issues facing the biopharma industry, but goes on to tell the story of what happened last year and this first quarter in terms of the stock market, M&A and financing (including IPOs) activity, where it is headed, and the implications for senior management.

Pharm Exec convenes a panel of biopharma executives responsible for the Latin America business to discuss investment, market access, and reimbursement issues in this key and challengingly diverse growth market for the life sciences industry

Global market access analyst Neil Grubert discusses what are likely to be some of the key trends in market access this year and beyond, and the implications for the life sciences industry.

Simon Webster looks at the role of intellectual property (IP) management in protecting pharmaceutical company products.

A new approach to reviving industry collaborations.

The key steps to easing rising complexity and cost factors.

How can Pharma balance the need to access to patient data and still respect patient privacy? One approach is to access patients through third-party online communities, writes Peter Houston.

In a continent marked by stark differences in governance, growth and market potential, the best bets must be pursued off script.

How a Manufacturing Excellence program can deliver competitive advantage to a fast-changing global product mix-at lower cost, and with an unexpected workforce dividend to boot.

However conservative and heavily regulated the drugs business, it too must transform itself to exploit digital opportunities - if only to ward off disruption, says Elvis Paćelat.

Biopharma companies are increasingly leveraging product portfolios to own and dominate strategically important therapeutic areas.

An industry-based working group presents a common standards and definition framework for “Access” competencies in pharma-as a starting point in solving the current shortage of talent and leaders for this widening set of activities.

Loss of exclusivity (LOE) doesn’t have to be the death knell for branded drug revenue streams. The key approaches to preserving meaningful value well into the post-patent-loss future are outlined.

Dan Wetherill offers three priorities for how pharma companies can better use data analytics to engage customers.